|
Q3 FY2025
As of Mar 31, 2025
|
Q2 FY2025
As of Dec 31, 2024
|
Q1 FY2025
As of Sep 30, 2024
|
Q4 FY2024
As of Jun 30, 2024
|
Q3 FY2024
As of Mar 31, 2024
|
Q2 FY2024
As of Dec 31, 2023
|
Q1 FY2024
As of Sep 30, 2023
|
Q4 FY2023
As of Jun 30, 2023
|
Q3 FY2023
As of Mar 31, 2023
|
Q2 FY2023
As of Dec 31, 2022
|
Q1 FY2023
As of Sep 30, 2022
|
Q3 FY2022
As of Mar 31, 2022
|
Q2 FY2022
As of Dec 31, 2021
|
Q1 FY2022
As of Sep 30, 2021
|
Q4 FY2021
As of Jun 30, 2021
|
Q3 FY2021
As of Mar 31, 2021
|
Q2 FY2021
As of Dec 31, 2020
|
Q1 FY2021
As of Sep 30, 2020
|
Q4 FY2020
As of Jun 30, 2020
|
Q3 FY2020
As of Mar 31, 2020
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current Assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Marketable securities | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Other assets: | ||||||||||||||||||||
| Investments | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||||||||||||||||||||
| Current Liabilities | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Sub-fund obligations | ||||||||||||||||||||
| Accrued expenses | ||||||||||||||||||||
| Short-term loans and notes payable | ||||||||||||||||||||
| Convertible notes payable | ||||||||||||||||||||
| Due to officers | ||||||||||||||||||||
| Due to officers and directors | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total due to officers and directors | ||||||||||||||||||||
| Advances from customers | ||||||||||||||||||||
| Derivative liabilities and Note Discount | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Stockholders’ deficit: | ||||||||||||||||||||
| Preferred Stock, $0.001 par value; 500,000,000 shares authorized. 600,000 shares of Class B Series I issued and outstanding as of 3/31/2025 and 6/30/2024 respectively. Par value: | ||||||||||||||||||||
| Class B Series I Preferred Stock | ||||||||||||||||||||
| Total preferred Stock, $0.001 par value; 500,000,000 shares authorized. 600,000 shares of Class B Series I issued and outstanding as of 3/31/2025 and 6/30/2024 respectively. Par value: | ||||||||||||||||||||
| APIC - Class B Series I | ||||||||||||||||||||
| Class B Series I Preferred Stock | ||||||||||||||||||||
| Total Preferred Stock | ||||||||||||||||||||
| Common stock, $0.001 par value; 60 billion shares authorized; 46,873,940,565 shares issued and outstanding on 3/31/2025; 60 billion shares authorized and 46,873,940,565 shares issued and outstanding on 6/30/2024, respectively, adjusted for 1 for 1,500 reverse split effective March 15, 2012. Par value: | ||||||||||||||||||||
| APIC - Common Stock | ||||||||||||||||||||
| Common Stock to be issued | ||||||||||||||||||||
| Common Stock to be cancelled | ||||||||||||||||||||
| Treasury stock: 484,767 shares as of 3/31/25 and 6/30/24, respectively - cost method. | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total Acc. Other Comprehensive Income (Loss) | ||||||||||||||||||||
| Total stockholders’ deficit | ||||||||||||||||||||
| Total liabilities and stockholders’ deficit | ||||||||||||||||||||
Loading...
